Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -6.03, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.63M shares, decreasing 0.59% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 37.73K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.